<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637403</url>
  </required_header>
  <id_info>
    <org_study_id>100.2.C.002</org_study_id>
    <nct_id>NCT00637403</nct_id>
  </id_info>
  <brief_title>Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Assess the Effect of Renal Impairment on the Pharmacokinetic Characteristics, Safety, and Tolerability of Megestrol Acetate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>SFBC Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg&#xD;
      dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with&#xD;
      varying degrees of renal impairment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty finding the required subject population&#xD;
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic blood samples</measure>
    <time_frame>predose and serially through 264 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine collection</measure>
    <time_frame>Predose and serially through 264 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with severe renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with end stage renal disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr &gt;80 mL/min)</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - &lt;50 mL/min)</description>
    <arm_group_label>III</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr &lt;30 mL/min and not on hemodialysis)</description>
    <arm_group_label>IV</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose</description>
    <arm_group_label>V</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Subjects with Normal Renal Function&#xD;
&#xD;
          1. BMI ≥18 kg/m2 and ≤35 kg/m2&#xD;
&#xD;
          2. Females of child-bearing potential must use an adequate and reliable method of&#xD;
             contraception. Postmenopausal females must be postmenopausal ≥1 year and have elevated&#xD;
             serum FSH&#xD;
&#xD;
          3. Able to provide written informed consent&#xD;
&#xD;
          4. Normal renal function, defined as estimated creatinine clearance (CLcr) &gt;80 mL/min at&#xD;
             screening&#xD;
&#xD;
        Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD&#xD;
&#xD;
        Meet inclusion criteria 1 through 3 for healthy subjects and the following criteria:&#xD;
&#xD;
          1. Renal impairment defined as creatinine clearance &lt;80 mL/min as determined using the&#xD;
             Cockroft-Gault formula. Subjects grouped according to degree of renal dysfunction:&#xD;
             mild (CLcr = &gt;50 and ≤80 mL/min), moderate (CLcr = &gt;30 and ≤50 mL/min), or severe&#xD;
             (CLcr = ≤30 mL/min)&#xD;
&#xD;
          2. Renal Impairment subjects must have evidence of stable renal impairment. Defined as&#xD;
             having CLcr values within 25% of each other from 2 separately measured serum&#xD;
             creatinine clearances using the Cockroft-Gault formula&#xD;
&#xD;
          3. ESRD subjects require hemodialysis for at least 3 months&#xD;
&#xD;
          4. Subjects with renal impairment or ESRD may have clinical laboratory test result&#xD;
             deviations that are judged by the Investigator to be consistent with the renal&#xD;
             condition of the subject or of no additional clinical significance for this study&#xD;
&#xD;
          5. Subjects with renal impairment or ESRD, must have stable underlying medical conditions&#xD;
             for at least 90 days prior to the start of study participation&#xD;
&#xD;
          6. Renal impaired subjects may smoke up to 5 cigarettes per day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy Subjects with Normal Renal Function&#xD;
&#xD;
          1. Clinically significant (history of or active) cardiac, hepatic, renal, pulmonary,&#xD;
             endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or&#xD;
             psychiatric disease that could put the subject at increased risk or could interfere&#xD;
             with the objectives of the study&#xD;
&#xD;
          2. Presence of any screening laboratory values outside the range of normal values and&#xD;
             deemed clinically significant by the Investigator&#xD;
&#xD;
          3. Use of a prescription drug within 14 days of study start, a non-prescription drug&#xD;
             within 7 days of study start, or need of concomitant medication during the study&#xD;
&#xD;
          4. Use of any drugs or herbal products known to inhibit or induce liver enzymes involved&#xD;
             in drug metabolism (CYP P450) within 30 days prior to 1st dose&#xD;
&#xD;
          5. History of allergic reaction or serum sickness to any drug or drug metabolites&#xD;
&#xD;
          6. Whole blood donation within 56 days prior to the first MA-CS dose or plasma donation&#xD;
             within 7 days prior to the first MA-CS dose&#xD;
&#xD;
          7. Positive test for HIV antibody or hepatitis B surface antigen (positive HIV or&#xD;
             hepatitis C antibody for ESRD subjects are acceptable)&#xD;
&#xD;
          8. Presence of drugs of abuse and/or alcohol&#xD;
&#xD;
          9. Participation in another investigational drug study within 30 days prior to the first&#xD;
             MA-CS dose&#xD;
&#xD;
         10. History of recent drug abuse or alcohol addiction during past 2 years&#xD;
&#xD;
         11. Pregnant or breastfeeding&#xD;
&#xD;
         12. Consumption of grapefruit containing foods and beverages within 7 days prior to the&#xD;
             first MA-CS dose&#xD;
&#xD;
         13. History of recurrent thromboembolic events, a thromboembolic event in past three&#xD;
             months, or those still receiving long-term anticoagulation for thromboembolism&#xD;
&#xD;
        Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD&#xD;
&#xD;
        Excluded if subjects meet exclusion criteria 4 through 13 for healthy subjects and the&#xD;
        following criteria:&#xD;
&#xD;
          1. Unstable disease defined as concurrent medical conditions that change significantly&#xD;
             within 90 days&#xD;
&#xD;
          2. Changes in concomitant medications within 14 days prior to first dose administration&#xD;
             or expected changes during study participation&#xD;
&#xD;
          3. Subjects with a renal transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C Lasseter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn D. Kramer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Par Pharmaceutical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC International</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal impairment</keyword>
  <keyword>end stage renal disease</keyword>
  <keyword>megestrol acetate</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>renal dialysis</keyword>
  <keyword>kidney failure, chronic</keyword>
  <keyword>renal insufficiency</keyword>
  <keyword>Megace ES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

